米国の子宮筋腫治療機器の市場規模、シェア、動向分析レポート：技術別、治療モード別、セグメント予測、2025～2030年

米国の子宮筋腫治療機器市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の子宮筋腫治療機器の市場規模は2030年までに47億1,000万米ドルに達すると予測され、2025年から2030年にかけてCAGR 9.3％で拡大すると予測されています。

米国の子宮筋腫治療機器産業は、子宮筋腫治療の選択肢に対する意識の高まり、低侵襲手術の進歩、子宮摘出手術に代わる子宮温存手術に対する需要の高まりにより、大きな成長を遂げています。加えて、生殖年齢の女性における子宮筋腫の有病率の増加、革新的な治療装置の利用可能性は、市場拡大を促進する主な要因です。

子宮筋腫治療機器の革新は、患者の治療を変革し続けています。最近のFDA承認と製品発売により、より効果的で侵襲の少ない治療オプションへの道が開かれました。2024年9月、症候性子宮筋腫の低侵襲ソリューションに特化した医療機器企業であるGynesonics Inc.は、Sonata System用の新しいSMART OS 2.4ソフトウェア技術のリリースを発表しました。この革新的な治療は、最初で唯一の子宮内超音波システムと独自の先進的なラジオ波焼灼装置を組み合わせたもので、症候性子宮筋腫の治療に、切開を必要とせず、子宮を温存し、経頸管的な選択肢を提供します。このような進歩は、手技のリスクを軽減しながら患者の転帰を改善するという業界のコミットメントを強調するものです。

市場は非外科的で子宮温存の治療アプローチにシフトしています。子宮摘出術のような伝統的な外科的処置は、回復時間の短縮、合併症の減少、患者の生活の質の向上を提供する侵襲性の低い方法に取って代わられつつあります。子宮鏡下子宮筋腫核出術、腹腔鏡下子宮筋腫核出術、非侵襲的超音波療法は、患者やヘルスケアプロバイダーの間で人気を集めています。

継続的な技術の進歩、低侵襲手術に対する保険適用の拡大、女性のリプロダクティブ・ヘルスへの関心の高まりにより、米国の子宮筋腫治療機器産業は持続的な成長を遂げようとしています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の子宮筋腫治療機器市場の変数、動向、および範囲

• 市場系統の見通し
  • 付随市場の見通し
• 市場力学
  • 市場ドライバー分析
  • 市場抑制要因分析
• 米国の子宮筋腫治療機器市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国の子宮筋腫治療機器市場：技術別推定・動向分析

• セグメントダッシュボード
• 米国の子宮筋腫治療機器市場における技術別変動分析
• 米国の子宮筋腫治療機器市場規模と動向分析（技術別、2018～2030年）
• 外科手術の技術
  • 子宮摘出術
  • 子宮筋腫摘出術
• 腹腔鏡手術
  • 腹腔鏡下子宮筋腫摘出術
  • 筋融解
• アブレーション技術
  • マイクロ波アブレーション
  • 熱水アブレーション
  • 凍結療法
  • 超音波アブレーション
• 塞栓術

第5章 米国の子宮筋腫治療機器市場：治療モード別推定・動向分析

• セグメントダッシュボード
• 米国の子宮筋腫治療機器市場における治療モード別変動分析
• 米国の子宮筋腫治療機器市場規模と動向分析（治療モード別、2018年～2030年）
• 侵襲的治療
• 低侵襲治療
• 非侵襲的治療

第6章 競合情勢

• 市場参入企業の分類
• 主要企業プロファイル
• Medtronic
• Stryker
• Boston Scientific Corporation
• Insightec.
• CooperSurgical Inc.
• Hologic, Inc.
• CONMED Corporation.
• Merit Medical Systems.
• Minerva Surgical, Inc.

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviation
• Table 3. U.S. Uterine Fibroids Treatment Devices Market, By Technology, 2018 - 2030 (USD Million)
• Table 4. U.S. Uterine Fibroids Treatment Devices Market, By Mode of Treatment, 2018 - 2030 (USD Million)
• Table 5. Participant's Overview
• Table 6. Financial Performance
• Table 7. Product Benchmarking
• Table 8. Strategic Initiatives

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 U.S. Uterine Fibroids Treatment Devices Market, Market Segmentation
• Fig. 7 Market Driver Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Analysis (Current & Future Impact)
• Fig. 9 Market Opportunity Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Analysis (Current & Future Impact)
• Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 12 Porter's Five Forces Analysis
• Fig. 13 Regional Marketplace: Key Takeaways
• Fig. 14 U.S. Uterine Fibroids Treatment Devices Market, for Surgical Techniques, 2018 - 2030 (USD Million)
• Fig. 15 U.S. Uterine Fibroids Treatment Devices Market, for Hysterectomy, 2018 - 2030 (USD Million)
• Fig. 16 U.S. Uterine Fibroids Treatment Devices Market, for Myomectomy, 2018 - 2030 (USD Million)
• Fig. 17 U.S. Uterine Fibroids Treatment Devices Market, for Laparoscopic Techniques, 2018 - 2030 (USD Million)
• Fig. 18 U.S. Uterine Fibroids Treatment Devices Market, for Laparoscopic Myomectomy, 2018 - 2030 (USD Million)
• Fig. 19 U.S. Uterine Fibroids Treatment Devices Market, for Myolysis, 2018 - 2030 (USD Million)
• Fig. 20 U.S. Uterine Fibroids Treatment Devices Market, for Ablation Techniques, 2018 - 2030 (USD Million)
• Fig. 21 U.S. Uterine Fibroids Treatment Devices Market, for Microwave Ablation, 2018 - 2030 (USD Million)
• Fig. 22 U.S. Uterine Fibroids Treatment Devices Market, for Hydrothermal Ablation, 2018 - 2030 (USD Million)
• Fig. 23 U.S. Uterine Fibroids Treatment Devices Market, for Cryoablation, 2018 - 2030 (USD Million)
• Fig. 24 U.S. Uterine Fibroids Treatment Devices Market, for Ultrasound Ablation, 2018 - 2030 (USD Million)
• Fig. 25 U.S. Uterine Fibroids Treatment Devices Market, for High Intensity Focused Ultrasound (HIFU), 2018 - 2030 (USD Million)
• Fig. 26 U.S. Uterine Fibroids Treatment Devices Market, for MRI-guided Focused Ultrasound (MRgFUS), 2018 - 2030 (USD Million)
• Fig. 27 U.S. Uterine Fibroids Treatment Devices Market, for Embolization Techniques, 2018 - 2030 (USD Million)
• Fig. 28 U.S. Uterine Fibroids Treatment Devices Market, for Invasive Treatment, 2018 - 2030 (USD Million)
• Fig. 29 U.S. Uterine Fibroids Treatment Devices Market, for Minimally Invasive Treatment, 2018 - 2030 (USD Million)
• Fig. 30 U.S. Uterine Fibroids Treatment Devices Market, for Non-invasive Treatment, 2018 - 2030 (USD Million)

U.S. Uterine Fibroids Treatment Devices Market Growth & Trends:

The U.S. uterine fibroids treatment devices market size is anticipated to reach USD 4.71 billion by 2030 and is anticipated to expand at a CAGR of 9.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The U.S. uterine fibroids treatment devices industry is experiencing significant growth due to the rising awareness of fibroid treatment options, advancements in minimally invasive procedures, and increasing demand for uterus-preserving alternatives to hysterectomy. In addition, the growing prevalence of uterine fibroids among women of reproductive age and the availability of innovative treatment devices are key factors driving market expansion.

Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry's commitment to improving patient outcomes while reducing procedural risks.

The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.

With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women's reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.

U.S. Uterine Fibroids Treatment Devices Market Report Segmentation

• Based on technology, the surgical technologies segment dominates the market with the largest revenue share owing to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions.
• Based on mode of treatment, the invasive treatment segment dominates the market with the largest revenue share owing to the high adoption of hysterectomy and myomectomy procedures, which offer definitive fibroid removal. Advancements in laparoscopic and robotic-assisted surgeries, along with strong insurance coverage, further solidified its market dominance.
• In January 2025, Hologic, Inc. acquired Gynesonics, Inc., a privately held company specializing in minimally invasive solutions for uterine fibroid treatment, for approximately USD 350 million. Gynesonics is renowned for its Sonata System, an innovative technology that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat symptomatic uterine fibroids without incisions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Third Party Perspective
  • 1.3.5. Primary research
  • 1.3.6. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Uterine Fibroids Treatment Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of uterine fibroids
    • 3.2.1.2. Advancements in minimally invasive procedures
    • 3.2.1.3. Increasing awareness and early diagnosis
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced treatment devices
• 3.3. U.S. Uterine Fibroids Treatment Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Uterine Fibroids Treatment Devices Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Uterine Fibroids Treatment Devices Market Technology Movement Analysis
• 4.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. Surgical Techniques
  • 4.4.1. Surgical Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Hysterectomy
    • 4.4.2.1. Hysterectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Myomectomy
    • 4.4.3.1. Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Laparoscopic Techniques
  • 4.5.1. Laparoscopic Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Laparoscopic Myomectomy
    • 4.5.2.1. Laparoscopic Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Myolysis
    • 4.5.3.1. Myolysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Ablation Techniques
  • 4.6.1. Ablation Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Microwave Abalation
    • 4.6.2.1. Microwave Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Hydrothermal Abalation
    • 4.6.3.1. Hydrothermal Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Cyroablation
    • 4.6.4.1. Cyroablation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Ultrasound Abalation
    • 4.6.5.1. Ultrasound Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5.2. High Intensity Focused Ultrasound (HIFU)
      • 4.6.5.2.1. High Intensity Focused Ultrasound (HIFU) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5.3. MRI-guided Focused Ultrasound (MRgFUS)
      • 4.6.5.3.1. MRI-guided Focused Ultrasound (MRgFUS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Embolization Techniques
  • 4.7.1. Embolization Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Uterine Fibroids Treatment Devices Market: Mode of Treatment Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Uterine Fibroids Treatment Devices Market Mode of Treatment Movement Analysis
• 5.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Mode of Treatment, 2018 to 2030 (USD Million)
• 5.4. Invasive Treatment
  • 5.4.1. Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Minimally Invasive Treatment
  • 5.5.1. Minimally Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Non-invasive Treatment
  • 5.6.1. Non-invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Key Company Profiles
  • 6.2.1. Medtronic
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Financial Performance
    • 6.2.1.3. Service Benchmarking
    • 6.2.1.4. Strategic Initiatives
• 6.3. Stryker
  • 6.3.1.1. Company Overview
  • 6.3.1.2. Financial Performance
  • 6.3.1.3. Service Benchmarking
  • 6.3.1.4. Strategic Initiatives
• 6.4. Boston Scientific Corporation
  • 6.4.1.1. Company Overview
  • 6.4.1.2. Financial Performance
  • 6.4.1.3. Service Benchmarking
  • 6.4.1.4. Strategic Initiatives
• 6.5. Insightec.
  • 6.5.1.1. Company Overview
  • 6.5.1.2. Financial Performance
  • 6.5.1.3. Service Benchmarking
  • 6.5.1.4. Strategic Initiatives
• 6.6. CooperSurgical Inc.
  • 6.6.1.1. Company Overview
  • 6.6.1.2. Financial Performance
  • 6.6.1.3. Service Benchmarking
  • 6.6.1.4. Strategic Initiatives
• 6.7. Hologic, Inc.
  • 6.7.1.1. Company Overview
  • 6.7.1.2. Financial Performance
  • 6.7.1.3. Service Benchmarking
  • 6.7.1.4. Strategic Initiatives
• 6.8. CONMED Corporation.
  • 6.8.1.1. Company Overview
  • 6.8.1.2. Financial Performance
  • 6.8.1.3. Service Benchmarking
  • 6.8.1.4. Strategic Initiatives
• 6.9. Merit Medical Systems.
  • 6.9.1.1. Company Overview
  • 6.9.1.2. Financial Performance
  • 6.9.1.3. Service Benchmarking
  • 6.9.1.4. Strategic Initiatives
• 6.10. Minerva Surgical, Inc.
  • 6.10.1.1. Company Overview
  • 6.10.1.2. Financial Performance
  • 6.10.1.3. Service Benchmarking
  • 6.10.1.4. Strategic Initiatives